Abstract: FR-PO1043
Dapagliflozin in Kidney Transplant Patients with Diabetes
Session Information
- Transplantation: Clinical - Pharmacology and Nonkidney Solid Organ Transplants
November 07, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2102 Transplantation: Clinical
Authors
- ElSharkawy, Magdy, Ain Shams University Faculty of Medicine, Cairo, Cairo Governorate, Egypt
- Teama, Nahla Mohamed, Ain Shams University Faculty of Medicine, Cairo, Cairo Governorate, Egypt
- Haddad, Omar Abdelmoez, Ain Shams University Faculty of Medicine, Cairo, Cairo Governorate, Egypt
- Tawfik, Ahmed, Ain Shams University Faculty of Medicine, Cairo, Cairo Governorate, Egypt
Background
This study evaluates the clinical impact of dapagliflozin in diabetic patients following renal transplantation.
Methods
This randomized controlled clinical trial was conducted on 72 stable post-renal transplantation diabetic patients, equally assigned to dapagliflozin and control .All patients received standard care , with the SGLT2i group receiving an additional 10 mg dapagliflozin. Baseline characteristics were well-balanced. After 6 months of follow-up, primary outcomes included 2-hour post-prandial levels, HbA1c, changes in mean body weight, eGFR, and the number of urinary tract infections
Results
Both groups exhibited body weight reduction with the intervention group showing median weight loss of -4.00 kg, which was statistically significant than the control group which showed a median change of -0.75 kg . There was no statistically significant difference in eGFR (P=0.54) or 2-hour post-prandial levels (P= 0.25) , no recorded episodes of major hypoglycaemia.Also there was no statistically significant difference regarding attacks of urinary tract infections, drug interactions , no attacks of volume depletion, diabetic ketoacidosis or ischemic insults
The use of other oral hypoglycaemic drugs decreased in the intervention group, with 64% of patients not needing them, compared to only 25% in the control group . There was also a significant downward trend in the number needed in the intervention group (P=0.08). The need for basal insulin decreased to 13.9% in the intervention group, compared to 38.9% in the control group. The intervention group showed a lower need for short-acting insulin, at 8.3%, compared to 16.7% in the control group
Conclusion
SGLT2 inhibitors may be considered in managing post-transplant DM in renal transplant recipients, as they are anti-diabetic drugs with significant effects on weight reduction and glycemic control. Also they can be used to reduce the number of other oral hypoglycemic drugs and the dosage of short-acting and basal insulin. Monitoring is required, particularly for urinary tract infections
Comparison regarding number of OHG